Biotin-Doxorubicin Liposome (PEGylated) (CAT#: CLBD013LY)

Description
This formulation is Doxorubicin Liposome (PEGylated) with the biotin group. Biotinylated liposome can be conjugated noncovalently with streptavidin through either direct interaction with the protein/antibody conjugated to streptavidin or by coupling with other biotinylated proteins using streptavidin as a bridging molecule. Both avidin and streptavidin form strong noncovalent bond with biotin.
Lipid Composition
HSPC, Cholesterol, DSPE-PEG(2000), DSPE-PEG(2000)-Biotin
Encapsulated Drug
Doxorubicin
Buffer
Ammonium sulfate, pH 7.4
Storage
Store in dark at +4°C and do not freeze
Size
100 nm
Quantity
5mL (available in lyophilized powder)
Molecular Structure
Download
DataSheet MSDS
FAQs Published Data Customer Reviews Related Sections
  1. What is the main advantage of incorporating biotin into doxorubicin liposomes?

    Biotin is used to enhance the targeting capabilities of doxorubicin liposomes. Through the high-affinity binding interaction between biotin and avidin or streptavidin, these liposomes can be directed more efficiently to biotin-receptor expressing cells, improving the delivery of doxorubicin to target cancer cells.

  2. How does the PEGylation of biotin-doxorubicin liposomes contribute to their function?

    PEGylation extends the circulation time of the liposomes in the bloodstream by creating a hydrophilic barrier around the liposomes. This reduces opsonization by the mononuclear phagocyte system, thereby preventing premature clearance from the bloodstream and allowing more time for the liposomes to reach and accumulate at the tumor site.

  3. Can biotin-doxorubicin liposomes reduce the side effects associated with free doxorubicin?

    Yes, by encapsulating doxorubicin within liposomes, the direct exposure of the drug to healthy tissues is minimized, reducing the typical side effects associated with free doxorubicin such as cardiotoxicity and myelosuppression. This targeted approach allows for a higher concentration of the drug to reach the tumor with less systemic toxicity.

  4. How are biotin-doxorubicin liposomes administered?

    These liposomes are typically administered intravenously to ensure that they can circulate throughout the body and reach the tumor site effectively. The administration route allows the liposomes to exploit the enhanced permeability and retention effect of tumors.

Biotin-Doxorubicin Liposome (PEGylated)-fig1


Biodistribution of EGFR-targeted and non-targeted doxorubicin-liposomes in mice bearing i.p. SKOV-3 xenografts.

This study focused at the tumor-targeting effects of biotin-doxorubicin liposome (PEGylated) that have been modified with antibodies. Researchers incubated a complex of neutravidin and biotinylated cetuximab with biotinylated liposomes to obtain cetuximab-biotin-doxorubicin-liposomes. Subsequently, they examined the distribution and tumor accumulation of cetuximab-biotin-doxorubicin-liposomes (targeted) and biotin-doxorubicin-liposomes (non-targeted) in SKOV-3 xenograft bearing mice. The figure illustrates the doxorubicin concentrations in various tissues and serum 24 hours post-administration. The results indicate that the targeted liposome group had higher levels of doxorubicin in the liver and spleen compared to the non-targeted liposome group, while demonstrating lower levels in the serum. This study demonstrates the potential of biotin-doxorubicin liposomes for developing targeted delivery systems to improve doxorubicin efficiency in reaching the liver and spleen.

Lehtinen, Julia, et al. "Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma." PloS one 7.7 (2012): e41410. Under Open Access license CC BY 4.0, without modification.

Distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

  • Precision in Targeting
    Creative Biolabs' biotin-doxorubicin liposomes have improved targeting precision, enhancing drug delivery to biotin-receptor positive cancer cells with minimal off-target effects.
  • Breakthrough in Cancer Treatment
    Utilizing the unique affinity of biotin for avidin, these liposomes offer a breakthrough in site-specific drug delivery, significantly reducing the dosage required for therapeutic effect.
  • Superior Targeting and Reduction of Side Effects
    Creative Biolabs' biotin-doxorubicin liposomes excel in targeting, substantially reducing the side effects typically associated with doxorubicin, enhancing patient compliance in our clinical trials.
  • Leading Edge in Nanocarrier Technology
    The biotin-doxorubicin liposomes from Creative Biolabs represent the leading edge in nanocarrier technology, providing targeted, effective cancer treatment solutions.

Click the button below to contact us or submit your feedback about this product.

For Research Use Only. Not For Clinical Use

Online Inquiry

Advertisement